Abstract
During the course of constructing a natural product library for drug screening consisting of microbial culture extracts originated from marine samples, we evaluated natural product components profiles via UPLC TOF-MS and routine biological tests for cytotoxic and antibiotic activities for all of the culture extract samples. By combination of chemical screening and biological activities, we succeeded in discovering a 20-membered macrolactam antibiotic subsequently designated JBIR-150 (1) from a marine-derived actinomycete identified as Streptomyces sp. that was isolated from an Okinawan marine sediment. The chemical structure of 1 was determined by interpreting NMR spectroscopic and mass spectrometric data. Compound 1 exhibited moderate cytotoxicity against MESO-1 and Jurkat cells.
During the course of our screening program for new anticancer agents from Okinawan marine microorganisms, a new compound, designated JBIR-150 (1), was isolated from the culture broth of Streptomyces sp. OPMA00071. Chemical and spectroscopic analyses revealed that 1 belonged to the class of 20-membered polyene macrolactam antibiotics. Herein, we report the fermentation, isolation, structure elucidation, and preliminary biological activities of 1.
Strain OPMA00071 was isolated from marine sediments collected in Okinawa prefecture, Japan. The isolated strain was identified as Streptomyces sp. on the basis on 99.9% similarity in the 16S rDNA gene sequence to Streptomyces heliomycini. The producing strain was cultivated in 50-ml test tubes, each containing 15 ml of a seed medium consisting of 1.0% starch, 1.0% Hipolypepton, 1.0% molasses, and 1.0% meat extract at pH 7.2 (adjusted before sterilization). The test tubes were shaken on a reciprocal shaker (320 r.p.m.) at 27 °C for 2 days. Aliquots (2.5 ml) of the culture were transferred into 500-ml baffled Erlenmeyer flasks filled with 100 ml of a production medium consisting of 4 g β-cyclodextrin, 0.5 g glycerol, 2 g Pharmamedia, 0.5 mg CuSO4•5H2O, 0.5 mg MnCl2•4H2O, and 0.5 mg ZnSO4•7H2O, and cultured on a rotary shaker (180 r.p.m.) at 27 °C for 5 days.
The fermentation broth (2L) was centrifuged to obtain a mycelial cake, which was extracted with acetone (250 ml × 3). The extract was concentrated in vacuo, and the residual aqueous concentrate was successively washed with EtOAc followed by extraction with n-BuOH. The n-BuOH layer was then concentrated in vacuo. The dried residue (2.29 g) was triturated in MeOH (5 ml) and the residue was filtered using a Kiriyama-rohto device (Kiriyama, Tokyo, Japan) to afford JBIR-150 (1, 190.0 mg) as a colorless amorphous powder: [α]21D 163 (c 0.01, MeOH); UV λmax nm (log ɛ): 227 (4.4), 260 (4.2), 310 (3.8), and 324 (3.7) in MeOH; IR (ATR) νmax 3300 and 1630 cm−1 (hydroxy and amide carbonyl). Its molecular formula C28H39NO3 was established by an [M+H]+ ion at m/z 438.2977 (calcd for C28H40NO3, 438.3003) in a high-resolution electrospray ionization mass spectrometry.
Because 1 was insoluble in CH3OH, CH3CN, n-hexane, EtOAc, CHCl3, n-BuOH, and water, the NMR spectra were measured in DMSO-d6. The structure determination of 1 was executed based on a series of 2D NMR analyses such as double quantum filtered COSY (DQF-COSY), gradient-enhanced heteronuclear single quantum coherence with adiabatic pulses (HSQCAD), and gradient-selected heteronuclear multiple bond correlation using adiabatic pulses (HMBCAD). The 13C and 1H NMR data for 1 are listed in Table 1.
The well-resolved DQF-COSY spectrum of 1 indicated two partial structures. The first one is ranging from a doublet olefinic methine proton 2-H (δH 5.79) to an olefinic methine proton 13-H (δH 6.15) through olefinic methine protons 3-H (δH 6.65), 4-H (δH 6.19), 5-H (δH 6.14), 6-H (δH 5.91), and 7-H (δH 5.44), an oxymethine proton 8-H (δH 4.53), and aliphatic methylene protons 9-H2 (δH 1.44, 1.35), an oxymethine proton 10-H (δH 3.83), aliphatic methylene protons 11-H2 (δH 2.48, 2.24) and an olefinic methine protons 12-H (δH 5.89). The second one from olefinic methine proton 15-H (δH 5.87) to terminal methyl protons 27-H3 (δH 0.84) via olefinic methine protons 16-H (δH 6.27) and 17-H (δH 5.39), methylene protons 18-H2 (δH 2.32, 1.82), a nitrogen-substituted methine proton 19-H (δH 3.74), methylene protons 20-H2 (δH 2.19), olefinic methine protons 21-H (δH 5.53), 22-H (δH 6.01), 23-H (δH 5.97), and 24-H (δH 5.57), and aliphatic methylene protons 25-H2 (δH 1.99) and 26-H2 (δH 1.34, 1.23). In the HMBC spectrum, 1H–13C long-range couplings from singlet methyl protons 28-H3 (δH 1.74) to olefinic quaternary carbon C-14 (δC 133.6) and olefinic methine carbons C-13 (δC 136.7) and C-15 (δC 130.1) connected C-13 and C-15 via C-14. 1H–13C Long-range couplings from olefinic protons H-13 and H-15 to C-28 also supported this connection. A macrolactam structure was established by the 1H–13C long-range couplings from the olefinic protons 2-H and 3-H and an amide proton (δH 7.39), which was spin coupled with 19-H, to an amide carbonyl carbon C-1 (δC 165.9). Based on the double bond equivalents of 1 and of the proton and carbon shifts, two hydroxy groups were substituted at the positions of C-8 and C-10. Thus, the gross structure of 1 was established as shown in Fig. 1.
The 2E, 4E, 6E, 12E, 14E, 16E, 21E, and 23E geometry was assigned based on the large 3JH,H values (J2,3 = J4,5 = J6,7 = J16,17 = J21,22 = J23,24 = 14–15 Hz) and ROESY correlations between 11-H2 and 13-H, 13-H and 15-H, and 15-H and 17-H.
Structurally related compounds are the 20-membered polyene macrolactams heronamide C and F and 8-deoxyheronamide C[1,2,3,4] from a marine-derived Streptomyces sp., which showed moderate cytotoxic activities. Compound 1 also exhibited cytotoxicity against human malignant mesothelioma MESO-1 and human T-lymphoma Jurkat cells [5], with IC50 values of 2.3 and 0.90 μM, respectively, and weak cytotoxic effects against human ovarian adenocarcinoma SKOV-3 at a concentration of 100 μM. Tests for further biological activities and biosynthetic studies of 1 are now underway.
References
Raju R, Piggott AM, Conte MM, Capon RJ. Heronamides A-C, new polyketide macrolactams from an Australian marine-derived Streptomyces sp. A biosynthetic case for synchronized tandem electrocyclization. Org Biomol Chem. 2010;8:4682–9.
Sugiyama R, Nishimura S, Kakeya H. Stereochemical reassignment of heronamide A, a polyketide macrolactam from Streptomyces sp. Tetrahedron Lett. 2013;54:1531–3.
Zhang W, et al. Heronamides D − F, Polyketide macrolactams from the deep-sea-derived Streptomyces sp. SCSIO 03032. J Nat Prod. 2014;77:10–3.
Sugiyama R, et al. Structure and biological activity of 8-deoxyheronamide C from a marine-derived Streptomyces sp.: Heronamides target saturated hydrocarbon chains in lipid membranes. J Am Chem Soc. 2014;136:5209–12.
Kawahara T, et al. Foxo3a inhibitors of microbial origin, JBIR-141 and JBIR-142. Org Lett. 2015;17:5476–9.
Acknowledgements
This work was supported in part by the grant “Project focused on developing key technology of discovering and manufacturing drug for next-generation treatment and diagnosis” from the Ministry of Economic, Trade and Industry (METI). The authors also thank OP Bio Factory for providing the collected strains.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Kawahara, T., Fujiwara, T., Kagaya, N. et al. JBIR-150, a novel 20-membered polyene macrolactam from marine-derived Streptomyces sp. OPMA00071. J Antibiot 71, 390–392 (2018). https://doi.org/10.1038/s41429-017-0010-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41429-017-0010-2
This article is cited by
-
Genome mining for macrolactam-encoding gene clusters allowed for the network-guided isolation of β-amino acid-containing cyclic derivatives and heterologous production of ciromicin A
Communications Chemistry (2023)
-
Screening of marine sediment-derived microorganisms and their bioactive metabolites: a review
World Journal of Microbiology and Biotechnology (2023)